<DOC>
	<DOCNO>NCT00921531</DOCNO>
	<brief_summary>Chemoembolization ( TACE ) use majority advance hepatocellular carcinoma . Randomized clinical trial indicate TACE improve overall survival patient good liver function ( Child-pugh A B ) . However , shortcoming TACE obvious : hypoxia induce neoangiogenesis blockage blood supply tumor ; repeat TACE deteriorate liver cirrhosis due toxicity chemotherapeutic agent parenchyma liver . Thalidomide report antiangiogenic antimetastatic effect . The objective adjuvant therapy thalidomide chemoembolization evaluate overall survival time progression .</brief_summary>
	<brief_title>Adjuvant Therapy With Thalidomide Chemoembolization Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Hepatocellular carcinoma confirm pathology identify radiological image typical feature Age ≥ 18 year ≤ 80 year At least one tumor nodule one unidimension ≥ 2 cm ChildPugh Class A B Total bilirubin ≤ 1.5 x upper limit normal ALT AST ≤ 2.0 x upper limit normal PTINR &lt; 2.3 , PTT &lt; 1.5 x upper limit normal Serum creatinine ≤ 1.5x upper limit normal Peripheral white blood cell count 3×10 ( 9 ) /L Peripheral platelet 50×10 ( 9 ) /L Expected survival time le 3 month ECOG score 02 Tumor thrombus main branch portal vein Tumor involvement 70 % whole liver With extrahepatic metastasis Prior systemic chemotherapy chemoembolization Congestive heart failure &gt; NYHA class 2 History HIV infection Active clinically serious infection ( &gt; 2 NCICTC Version 3.0 ) Recurrence HCC liver transplantation Pregnant breastfeeding Substance abuse , medical , psychological social condition may interfere patient 's participation study Known suspect allergy agent give association trial Patients unable swallow oral medication Inclined thrombosis Inclined hemorrhage active hemorrhage 1 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>thalidomide</keyword>
	<keyword>TACE</keyword>
	<keyword>Child-Pugh Class A B</keyword>
</DOC>